

HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

Non-Radiographic Axial Spondyloarthritis (nrx-SpA)

Avsola[®], Cimzia[®], Cosentyx[®], Inflectra[®], infliximab, Remicade[®], Renflexis[®], Taltz[®]

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department.

- For **Medical Pharmacy** please fax requests to: 801-213-1547
- For **Retail Pharmacy** please fax requests to: 385-425-4052

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 385-425-5094

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred/Non-Formulary:

- 1. 1st Line Preferred agents:**
 - A. Infliximab products: Avsola[®] (infliximab-axxq), Inflectra[®] (infliximab-dyyb), infliximab, Remicade (infliximab), Renflexis[®] (infliximab-abda)
- 2. 2nd line preferred agents with single step; after trial and failure of 1 preferred first line agent:**
 - A. Cimzia[®] (certolizumab), Taltz[®] (ixekizumab)
- 3. Non-Formulary agents with a triple step; after trial and failure of 1 preferred first line agent and 2 second line agents:**
 - A. Cosentyx[®] (secukinumab)

Product being requested: _____

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older with Non-Radiographic Axial Spondyloarthritis?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the requesting provider a rheumatologist or in consultation with one?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does documentation show an adequate trial and failure of at least one prescription strength nonsteroidal anti-inflammatory drug (NSAID) at the maximally tolerated dose, unless contraindicated?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the provider performed tuberculosis (TB) screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

5. For tumor necrosis factor inhibitors (TNFIs), has the provider preformed Hepatitis B screening prior to therapy initiation?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Does updated documentation show that the member has a continued medical need?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the provider performed continued tuberculosis screening during therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the provider performed continued Hepatitis B monitoring in HBV carriers?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

**** Failure to submit clinical documentation to support this request will result in a dismissal of the request.****

Policy: PHARM-HU-142
 Origination Date: 07/28/2022
 Reviewed/Revised Date: 08/24/2022
 Next Review Date: 08/24/2023
 Current Effective Date: 09/01/2022

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.